BeOne

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

FDA hands BeOne, Taiho approvals for blood cancers

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

Brukinsa data raises chemo-free hope for mantle cell lymphom...

FDA hands BeOne, Taiho approvals for blood cancers

FDA clears first all-oral combo for first-line CLL treatment

11 high-impact drugs to look out for in 2026

FDA starts priority review of BeOne's Venclexta rival

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Despite study bust, Vistagen still hopes to file anxiety dru...

Discover a new era of healthcare panel engagement: Grounded ...

BeOne

Editor's Picks